Literature DB >> 24127443

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Nancy E Thomas1, Klaus J Busam, Lynn From, Anne Kricker, Bruce K Armstrong, Hoda Anton-Culver, Stephen B Gruber, Richard P Gallagher, Roberto Zanetti, Stefano Rosso, Terence Dwyer, Alison Venn, Peter A Kanetsky, Pamela A Groben, Honglin Hao, Irene Orlow, Anne S Reiner, Li Luo, Susan Paine, David W Ollila, Homer Wilcox, Colin B Begg, Marianne Berwick.   

Abstract

PURPOSE: Although most hospital-based studies suggest more favorable survival with tumor-infiltrating lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic information beyond existing melanoma staging definitions. We addressed the issue in an international population-based study of patients with single and multiple primary melanomas. PATIENTS AND METHODS: On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of 2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with clinicopathologic features and survival by TIL grade were examined.
RESULTS: Independent predictors (P < .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee on Cancer (AJCC) tumor stage compared with TIL absence (P(trend) < .001). Death as a result of melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and 50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for age, sex, site, and AJCC tumor stage.
CONCLUSION: At the population level, higher TIL grade of primary melanoma is associated with a lower risk of death as a result of melanoma independently of tumor characteristics currently used for AJCC tumor stage. We conclude that TIL grade deserves further prospective investigation to determine whether it should be included in future AJCC staging revisions.

Entities:  

Mesh:

Year:  2013        PMID: 24127443      PMCID: PMC3821014          DOI: 10.1200/JCO.2013.51.3002

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

Authors:  Ralph J Tuthill; Joseph M Unger; P Y Liu; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Pathol       Date:  2002-10       Impact factor: 2.493

2.  Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.

Authors:  Trine O Jensen; Henrik Schmidt; Holger J Møller; Frede Donskov; Morten Høyer; Pia Sjoegren; Ib J Christensen; Torben Steiniche
Journal:  Cancer       Date:  2011-09-22       Impact factor: 6.860

3.  Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.

Authors:  R L Barnhill; J A Fine; G C Roush; M Berwick
Journal:  Cancer       Date:  1996-08-01       Impact factor: 6.860

4.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

Authors:  Esther Edlundh-Rose; Suzanne Egyházi; Katarina Omholt; Eva Månsson-Brahme; Anton Platz; Johan Hansson; Joakim Lundeberg
Journal:  Melanoma Res       Date:  2006-12       Impact factor: 3.599

Review 5.  Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features.

Authors:  David E Elder; Phyllis A Gimotty; DuPont Guerry
Journal:  Dermatol Ther       Date:  2005 Sep-Oct       Impact factor: 2.851

6.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 7.  AJCC melanoma staging update: impact on dermatopathology practice and patient management.

Authors:  Adriano Piris; Martin C Mihm; Lyn M Duncan
Journal:  J Cutan Pathol       Date:  2011-03-09       Impact factor: 1.587

8.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

9.  The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm).

Authors:  D E Elder; D Guerry; M VanHorn; S Hurwitz; L Zehngebot; L I Goldman; D LaRossa; R Hamilton; E E Bondi; W H Clark
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

10.  Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Authors:  M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini
Journal:  Eur J Cancer       Date:  2009-06-22       Impact factor: 9.162

View more
  100 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma.

Authors:  Sook Jung Yun; Shujing Liu; Meghan Buckley; Tao Wang; Suna Jin; Giorgos Karakousis; Madalyn G Peters; David E Elder; Phyllis A Gimotty; Xiaowei Xu
Journal:  Hum Pathol       Date:  2019-04-06       Impact factor: 3.466

3.  Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy.

Authors:  Lin Wang; Zhi-Wei Zhai; Deng-Bo Ji; Zhong-Wu Li; Jin Gu
Journal:  Int J Colorectal Dis       Date:  2015-05-03       Impact factor: 2.571

4.  Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.

Authors:  Nicholas J Taylor; Nancy E Thomas; Hoda Anton-Culver; Bruce K Armstrong; Colin B Begg; Klaus J Busam; Anne E Cust; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Diane E Nishri; Irene Orlow; Stefano Rosso; Alison J Venn; Roberto Zanetti; Marianne Berwick; Peter A Kanetsky
Journal:  Int J Cancer       Date:  2016-05-30       Impact factor: 7.396

Review 5.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy.

Authors:  Geoffrey T Gibney; Louis M Weiner; Michael B Atkins
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

6.  Emerging immunologic biomarkers: setting the (TNM-immune) stage.

Authors:  Janis M Taube
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 7.  Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.

Authors:  Mark B Faries
Journal:  Crit Rev Oncog       Date:  2016

Review 8.  Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).

Authors:  J Nicholas Bodor; Yanis Boumber; Hossein Borghaei
Journal:  Cancer       Date:  2019-11-06       Impact factor: 6.860

9.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

10.  Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.

Authors:  Nancy E Thomas; Sharon N Edmiston; Irene Orlow; Peter A Kanetsky; Li Luo; David C Gibbs; Eloise A Parrish; Honglin Hao; Klaus J Busam; Bruce K Armstrong; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway
Journal:  J Invest Dermatol       Date:  2018-05-09       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.